News

RAMP Welcomes 5 Startups into Spring 2023 Cohort

From designing battery electric spotter tractors to developing individualized neuro-oncology treatments for aggressive gliomas, the five companies accepted into RAMP’s Spring 2023 Cohort span the gamut of technology, health science and life science innovation.

“We are thrilled to welcome these inspiring entrepreneurs and help them accelerate their vision,” said RAMP director Lisa Garcia. “Not only are these companies working in fields vital to our economic, environmental and physical health, their success and growth will enhance the technology ecosystem of western Virginia.”

  • Cairina, Inc., located in Salem, provides technologies that non-invasively measure biologic fluid flow using clinically standard imaging protocols for personalized medicine applications.
  • Code One Training Solutions, of Roanoke, offers a tech-driven, revolutionary innovation for American Heart Association CPR certification.
  • MOVA Technologies, of Pulaski, specializes in air capture technology applying sustainable, circular principles to selectively capture and harvest air contaminants as valuable byproducts that can be sold and reused.
  • SchedulerHUB, based in Roanoke, is an intuitive scheduling and analytics platform for manufacturers to manage complex production projects.
  • Trova Commercial Vehicles, Inc., located in Pulaski, develops battery electric spotter tractors (designed to move trailers and cargo containers around ports, truck terminals and distribution centers) as well as class 8 diesel to electric conversion kits.

The community is invited to “Meet the Cohort” on April 13 at the Shenandoah Club in Roanoke. At the completion of RAMP’s 12-week cohort, the entrepreneurs will present to the community at “Demo Day,” tentatively scheduled for June 8.

As part of the RAMP-in-Residence experience, startups receive $20,000 in non-equity funding, expert 1:1 mentoring, and free office space with high-speed internet in downtown Roanoke’s Gill Building. RAMP alumni also receive two years of free membership in the Roanoke-Blacksburg Technology Council; one year of membership in Virginia BIO; three years of membership in the Shenandoah Club; membership in GAN for the lifetime of the company; discounted office space following completion of the 12-week program; and three additional years of ongoing support through Exit RAMP – a suite of ever-growing and developing coaching and support services.

Founded in 2017, RAMP (Regional Accelerator and Mentoring Program) has accelerated 38 companies to date that collectively employ more than 600 people and sell products and services to all 50 U.S. states and internationally. RAMP is an affiliate of Verge, a collaborative strategic alliance that includes the Roanoke-Blacksburg Technology Council established to grow the region’s innovation economy.

 

Recent News

04/15/2026

Gov. Spanberger and Homegrown Innovator Agrospheres Celebrate Launch of Virginia’s new Biomanufacturing Facility

AgroSpheres, Inc., a Charlottesville-based agricultural biotechnology company, officially opened its first commercial biomanufacturing facility, representing a milestone for AgroSpheres and the biotech ecosystem. Speakers at the ribbon-cutting ceremony included: Virginia Governor Abigail Spanberger, AgroSpheres co-founders CEO Payam Pourtaheri and CTO Ameer Shakeel, Albemarle County Chair of the Board of Supervisors Ned Gallaway, President of the

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.